Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients
emtek 2113 John PuetzSaint Louis University, Department of Pediatrics, St Louis, Missouri, USAAbstract: One of the last remaining clinical hurdles in the treatment of people with hemophilia is the development of inhibitors.Alloantibodies or autoantibodies directed at coagulation factors render the infusion of coagulation factor concentrates ineffec